Journal of the American College of Radiology
Volume 5, Issue 11 , Pages 1118-1124 , November 2008

Introduction to Value-Based Insurance Design

  • Aine Marie Kelly, MD, MS

      Affiliations

    • Department of Radiology, Division of Cardiothoracic Radiology, University of Michigan Medical Center, Ann Arbor, Michigan
    • Corresponding Author InformationCorresponding author and reprints: Aine Marie Kelly, MD, MS, University of Michigan Hospitals, Department of Radiology, Division of Cardiothoracic Radiology, B1 132K Taubman Center/5302, 1500 East Medical Center Drive, Ann Arbor, MI 48109-5302
    • ,
  • Paul Cronin, MD, MS

      Affiliations

    • Department of Radiology, Division of Cardiothoracic Radiology, University of Michigan Medical Center, Ann Arbor, Michigan
    • ,
  • Ruth C. Carlos, MD, MS

      Affiliations

    • Department of Radiology, Division of Magnetic Resonance Imaging, University of Michigan Medical Center, Ann Arbor, Michigan

References 

  1. World Health Organization. World health statistics 2007 highlights and tables: health systems. http://www.who.int/whosis/whostat2007_6healthsystems_nha.pdfAccessed September 23, 2008
  2. World Health Organization. World health statistics 2007 highlights and tables: health status: mortality. http://www.who.int/whosis/whostat2007_1mortality.pdfAccessed September 23, 2008
  3. Carlos RC. Value-driven health care: the provider perspective. J Am Coll Radiol.
  4. Catlin A, Cowan C, Hartmann L, et al. National health spending in 2006: a year of change for prescription drugs. Health Aff (Millwood). 2008;27:14–29
  5. Dunnick NR, Applegate KE, Arenson RL. The inappropriate use of imaging studies: a report of the 2004 Intersociety Conference. J Am Coll Radiol. 2005;2:401–406
  6. Fendrick AM, Chernew ME. Value-based insurance design: a “clinically sensitive” approach to preserve quality of care and contain costs. Am J Manag Care. 2006;12:18–20
  7. Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care. 2005;11:730–740
  8. Heisler M, Langa KM, Eby EL, et al. The health effects of restricting prescription medication use because of cost. Med Care. 2004;42:626–634
  9. Rice T, Matsuoka KY. The impact of cost-sharing on appropriate utilization and health status: a review of the literature on seniors. Med Care Res Rev. 2004;61:415–452
  10. Blustein J. Medicare coverage, supplemental insurance, and the use of mammography by older women. N Engl J Med. 1995;332:1138–1143
  11. Solanki G, Schauffler HH, Miller LS. The direct and indirect effects of cost-sharing on the use of preventive services. Health Serv Res. 2000;34:1331–1350
  12. Solanki G, Schauffler HH. Cost-sharing and the utilization of clinical preventive services. Am J Prev Med. 1999;17:127–133
  13. Chernew ME, Shah MR, Wegh A, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff (Millwood). 2008;27:103–112
  14. Fendrick AM, Smith DG, Chernew ME, Shah SN. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care. 2001;7:861–867
  15. Fendrick AM, Chernew ME. Value-based insurance design: aligning incentives to bridge the divide between quality improvement and cost containment. Am J Manag Care. 2006;12:SP5–SP10
  16. Chernew ME, Rosen AB, Fendrick AM. Value-based insurance design. Health Aff (Millwood). 2007;26:195–203
  17. Arrow KJ. Uncertainty and the welfare economics of medical care (1963). J Health Polit Policy Law. 2001;26:851–883
  18. Pauly MV. The economics of moral hazard: comment. Am Econ Rev. 1968;58:531–537
  19. Fendrick AM, Chernew ME. Value-based insurance design: a “clinically sensitive, fiscally responsible” approach to mitigate the adverse clinical effects of high-deductible consumer-directed health plans. J Gen Intern Med. 2007;22:890–891
  20. Fendrick AM, Chernew ME. “Fiscally responsible, clinically sensitive” cost sharing: contain costs while preserving quality. Am J Manag Care. 2007;13:325–327
  21. Kleinke JD. Access versus excess: value-based cost sharing for prescription drugs. Health Aff (Millwood). 2004;23:34–47
  22. Garber AM. Cost-effectiveness and evidence evaluation as criteria for coverage policy. Health Aff (Millwood). 2004;W4:284–296
  23. Newhouse JP. Reconsidering the moral hazard-risk avoidance tradeoff. J Health Econ. 2006;25:1005–1014
  24. Goldman DP, Joyce GF, Mandic PK. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am J Manag Care. 2006;12:21–28
  25. Mahoney JJ. Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care. 2005;11:S170–S176
  26. Garrett DG, Bluml BM. Patient self-management program for diabetes: first-year clinical, humanistic, and economic outcomes. J Am Pharm Assoc. 2005;45:130–137
  27. Bunting BA, Cranor CW. The Asheville Project: long-term clinical, humanistic, and economic outcomes of a community-based medication therapy management program for asthma. J Am Pharm Assoc. 2006;46:133–147
  28. Bunting BA, Smith BH, Sutherland SE. The Asheville Project: clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia. J Am Pharm Assoc. 2008;48:23–31
  29. University of Michigan. MHealthy: Focus on Diabetes. http://www.hr.umich.edu/mhealthy/improve/diabetes/index.htmlAccessed September 23, 2008
  30. Rosen AB. Indications for and utilization of ACE inhibitors in older individuals with diabetes (Findings from the National Health and Nutrition Examination Survey 1999 to 2002). J Gen Intern Med. 2006;21:315–319
  31. Rosen AB. Grounding coverage in value: a paradigm for linking quality and costs. Med Care. 2006;44:389–391
  32. Garber A, Goldman DP, Jena AN. The promise of health care cost containment. Health Aff (Millwood). 2007;26:1545–1547
  33. Lohr KN, Brook RH, Kamberg CJ, et al. Use of medical care in the RAND Health Insurance Experiment (Diagnosis- and service-specific analyses in a randomized controlled trial). Med Care. 1986;24(suppl):S187
  34. American College of Radiology. ACR Appropriateness Criteria®. http://www.acr.org/SecondaryMainMenuCategories/quality_safety/app_criteria.aspxAccessed September 23, 2008
  35. Van Tulder MW, Koes BW, Bouter LM. Conservative treatment of acute and chronic nonspecific low back pain: a systematic review of randomized controlled trials of the most common interventions. Spine. 1997;22:2128–2156
  36. Agency for Health Care Policy and Research. AHCPR management guidelines for acute low back pain. Washington, DC: Agency for Health Care Policy and Research; 1994;

 This study was funded in part by grant 1 K07 CA108664 01A1 from the National Cancer Institute (Bethesda, Md) and a Radiology Research Academic Fellowship from GE Medical Systems (Milwaukee, Wis) and the Association of University Radiologists (Oak Brook, Ill).

PII: S1546-1440(08)00329-3

doi: 10.1016/j.jacr.2008.06.014

Journal of the American College of Radiology
Volume 5, Issue 11 , Pages 1118-1124 , November 2008

Article Tools